Regeneron Pharmaceuticals, Inc. (REGN) Discusses Factor XI Development Program and Clinical Data in Hematology Pipeline Transcript

Operator

Welcome to the Regeneron conference call to discuss its Factor XI development program. My name is Shannon, and I will be your operator for today’s call. [Operator Instructions] Please note that this conference call is being recorded. I will now turn the call over to Ryan Crowe, Senior Vice President, Investor Relations. You may begin.

Ryan Crowe
Senior Vice President of Investor Relations & Strategic Analysis

Thank you, Shannon. Good morning, and welcome to the inaugural Regeneron Roundtable Investor Event, the first in a series of presentations that will spotlight key opportunities across our pipeline.

Today, we will focus on our Factor XI development program, which began initial Phase III studies earlier this year. Today’s roundtable features key R&D leaders from Regeneron, including Dr. George Yancopoulos, Board Co-Chair, President and Chief Scientific Officer; Dr. Andres Sirulnik, Senior Vice President and Clinical Development Unit Head, Hematology; and David — Dr. David Gutstein, Vice President and Global Program Head, Hematology.

Before we begin, I would like to remind you that remarks made today may include forward-looking statements about Regeneron, and each forward-looking statement is subject